ImmunityBio (IBRX) announced today that the Saudi Food and Drug Authority granted approval for ANKTIVA to treat non-muscle invasive bladder cancer. This follows their previous approvals in the US, UK, and conditional approval in the EU. The company plans to open a regional office in Saudi Arabia and is partnering with Biopharma Cigalah to handle distribution across the Middle East. Management also noted that enrollment for their separate trial in BCG-naive patients is ahead of schedule, with completion expected by Q2 2026.